Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses

 
• By Jessica Merrill

The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.

Girl Alone
Regeneron will go it alone with Libtayo • Source: Shutterstock

More from Anticancer

More from Therapy Areas